The importance of the number of NMDA receptors in the development of supersensitivity or tolerance to and dependence on morphine

Pharmacological Research

Volumn 39, Issue 4, 1999, Pages 311-319

  Koyuncuoglu, Hikmet ^a   Nurten, Asiye ^b   Yamantürk, Pinar ^a,b   Nurten, Rüstem ^a,b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Dependence; MK801; Morphine; Naltrexone; NMDA receptors; Supersensitivity; Tolerance

Indexed keywords

DIZOCILPINE; GLUTAMIC ACID; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALTREXONE; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG SENSITIVITY; DRUG TOLERANCE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RAT; RECEPTOR DENSITY; TAIL FLICK TEST;

EID: 0033119960     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0443     Document Type: Article

References (54)

1. Tao P-L, Law PY, Loh HH. Decrease in δ and μ opioid receptor binding capacity in rat brain after chronic etorphine treatment. J Pharmacol Exp Ther 1987; 240: 809-15.
2. Pert CB, Snyder SH. Opiate receptor binding-enhancement by opiate administration in vivo. Biochem Pharmacol 1976; 25: 847-53.
3. Klee WA, Streaty RA. Narcotic receptor sites in morphine-dependent rats. Nature (London) 1974; 248: 61-3.
4. Petruzzi R, Ferraro TN, Kürshner VC, Golden GT, Berrettini H. The effects of repeated morphine exposure on μ opioid receptor number and affinity in C57BL/6J and DBA72J mice. Life Sci 1997: 61: 2057-64.
5. Zadina JE, Chang SL, Ge L-J, Kastin AJ. μ opiate receptor downregulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cell. J Pharmacol Exp Ther 1993; 265: 254-62.
6. Tang AH, Collins RJ. Enhanced analgesic effects of morphine after chronic administration of naloxone in the rat. Eur J Pharmacol 1978; 47: 473-74.
7. Tempel A, Gardner EL, Zukin RS. Neurochemical and functional correlates of naltrexone-induced receptor upregulation. J Pharmacol Exp Ther 1985; 232: 439-44.
8. Yoburn BC, Goodman RR, Cohen AH, Pasternak GW, Inturrisi CE. Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment. Life Sci 1985; 36: 2325-32.
9. Yano I, Takemori AE. Inhibition by naloxone of tolerance and dependence in mice treated acutely or chronically with morphine. Res Comm Chem Pathol Pharmacol 1977; 16: 721-33.
10. Koyuncuoglu H, Genç E, Güngör M, Eroglu L, Sagduyu H. The antagonizing effect of aspartic acid on the brain levels of monoamines and free amino acids during the development of tolerance to and physical dependence on morphine. Psychopharmacology 1977; 54: 187-91.
11. Koyuncuoglu H, Güngör M, Eroglu L, Sagduyu H. The antagonising effect of aspartic acid on morphine withdrawal and levallorphan-precipitated abstinence syndrome signs and on associated changes in brain levels of free amino acids in the rat. Psychopharmacology 1979; 62: 89-95.
12. Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry 1973; 28: 784-91.
13. Ginzburg HM. Naltrexone: Its Clinical Utility. Department of Health and Human Services Publication (ADM) 1984: 884-1358.
14. Koyuncuoglu H, Aricioglu F. Previous chronic blockade of NMDA receptors intensifies morphine dependence in rats. Pharmacol Biochem Behav 1991; 39: 575-9.
15. Marek P, Ben Eliyahu S, Gold M, Liebeskind JC. Excitatory amino acid antagonist (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res 1991; 574: 77-81.
16. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991; 361: 83-5.
17. Trujillo KA, Akil H. Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonist. Brain Res 1994; 633: 178-188.
18. Gonzalez P, Cabello P, Germany A, Norris B, Contreras E. Decrease of tolerance to and physical dependence on morphine by glutamate receptor antagonist. Eur J Pharmacol 1997; 332: 257-62.
19. Elliot K, Hynansky A, Intrurrisi CE. Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain 1994a; 59: 361-8.
20. G-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa-opioids. Pain 1994b; 56: 69-75.
21. Meller ST, Gebhart GF. Nitric Oxide (NO) and nociceptive processing in the spinal cord. Pain 1993; 52: 127-36.
22. G-nitro L-arginine prevents morphine tolerance. Eur J Pharmacol 1992; 221: 399-400.
23. Koyuncuoglu H, Nurten A, Nurten R, Aricioglukartal F. Changes in kinetic parameters of NMDA receptors following subchronic administration of morphine, naltrexone and naloxone in the rat brain. Med Bull Istanbul 1997; 30: 74-9.
24. 3H]MK801 in brain synaptic membranes treated with Triton X-100. Brain Res 1989; 499: 305-14.
25. Yoneda Y, Ogita K. Heterogeneity of the N-methyl-D-aspartate receptor ionophore complex in rat brain, as revealed by ligand binding techniques. J Pharmacol Exp Ther 1991; 159: 86-96.
26. Emmelot P. Bos CJ, van Hoeven P, van Blitterswijk WJ. Isolation of plasma membranes from rat and mouse livers and hepatomas. In: Fleisher S, Packer L, eds., Methods in Enzymology. Vol. XXXI, Part A. London: Academic Press, 1974: 75-90.
27. Lowry OH, Rosebrough NJ, Far AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
28. Koyuncuoglu H, Dizdar Y, Aricioglu F, Sayin Ü. Effects of MK 801 on morphine physical dependence: Attenuation and intensification. Pharmacol Biochem Behav 1992; 43: 487-90.
29. Sofuoglu M, Sato J, Takemori AE. Maintenance of morphine dependence by naloxone in acutely dependent mice. J Pharmacol Exp Ther 1990; 254: 841-6.
30. Lutfy K, Yoburn BC. The role of opioid receptor density in morphine tolerance. J Pharmacol Exp Ther 1991; 256: 575-80.
31. Yoburn BC, Billings B, Duttaroy A. Opioid receptor regulation in mice. J Pharmacol Exp Ther 1993; 265: 314-20.
32. Akaoka H, Aston-Jones G. Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input. J Neurosci 1991; 11: 3830-9.
33. Koyuncuoglu H, Güngör M, Eroglu L, Sagduyu H. The alterations of some effects of morphine in rats by glutamic acid and glycine. Med Bull Istanbul Med Fac 1976; 9: 56-64.
34. Koyuncuoglu H, Güngör M, Sagduyu H, Eroglu L. The antagonistic effects of aspartic acid on some effects of morphine on rats. Eur J Phannacol 1974; 27: 148-50.
35. Lee Chang S-C J, Lutfy K, Sierra V, Yoburn BC. Dissociation of opioid receptor upregulation and functional supersensitivity. Pharmacol Biochem Behav 1991; 38: 853-9.
36. Arias MJ. Effect of naloxone on functional recovery after experimental spinal cord injury in the rat. Surg Neurol 1985; 23: 440-2.
37. Young W, DeCrescito V, Flamm ES, Blight AR, Gruner JA. Pharmacological therapy of acute spinal injury: Studies of high dose methyl-prednisolone and naloxone. Clin Neurosurg 1988; 33: 675-97.
38. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in the rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984; 43: 1369-74.
39. Hao J-X, Xu X-J, Seiger A, Wiesenfeld-Hallin Z. The excitatory amino acid receptor antagonist MK-801 prevents the hypersensitivity induced by spinal cord ischemia in rats. Exp Neurol 1991; 113: 182-191.
40. 3H]MK-801) binding to N-methyl-D-aspartate (NMDA) receptors in rat brain. Biochem Pharmacol 1995; 50: 1373-7.
41. Magnusson KR, Cotman CW. Effects of aging on NMDA and MK 801 binding sites in mice. Brain Res 1993; 604: 334-7.
42. 3H] MK-801 binding in long-sleep and short-sleep lines of mice. Alcohol 1996; 13: 315-20.
43. Martin DC, Plagenhoef M, Abraham J, Dennison RL, Aranstom RS. Volatile anaesthetics and glutamate activation of N-methyl-D-aspartate receptors. Biochem Pharmacol 1995; 49: 809-17.
44. 3H]MK-801 to brain regions and spinal cord of the rat. Brain Res 1994; 639: 269-74.
45. Bhargava HN, Reddy PL, Gudehithlu KP: Down-regulation of N-methyl-D-aspartate (NMDA) receptors of brain regions and spinal cord of rats treated chronically with morphine. Gen Pharmacol 1995; 26: 131-6.
46. 3H]MK-801 to brain regions and spinal cord of mice treated chronically with morphine. Gen Pharmacol 1996; 27: 91-4.
47. Bernstein MA, Welch SP. μ-opioid receptor down-regulation and cAMP-dependent protein kinase phosphorylation in a mouse model of chronic morphine tolerance. Mol Brain Res 1998; 55: 237-42.
48. Harris RA, Yamamoto H, Loh HH, Way EL. Discrete changes in brain calcium with morphine analgesia, tolerance-dependence and abstinence. Life Sci 1977; 20: 501-5.
49. Follesa P, Ticku MK. NMDA receptor upregulation: Molecular studies in cultured mouse cortical neurons after chronic antagonist exposure. J Neurosci 1996; 16: 2172-8.
50. Tiseo PJ, Cheng J, Pasternak GW, Inturrisi CE. Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY 274614: Assessment of opioid receptor changes. J Pharmacol Exp Ther 1994; 268: 195-201.
51. Cai Y.C, Ma L, Fan G-H, Zhao J, Jiang L-Z, Pei G. Activation of N-methyl-D-aspartate receptor attenuates acute responsiveness of δ-opioid receptors. Mol Pharmacol 1997; 51: 583-7.
52. Koyuncuoglu H, Saydam B. The treatment of heroin addicts with dextromethorphan: A double-blind comparison of dextromethorphan with chlorpromazine. Int J Clin Pharmacol Ther Toxicol 1990; 28: 147-52.
53. Koyuncuoglu H. The treatment with dextromethorphan of heroin addicts. In: Drug Addiction and AIDS. Loimer N, Schmidt R, Springer A, eds. Vienna: Springer, 1991: 320-9.
54. Koyuncuoglu H. The combination of tizanidine markedly improves the treatment with dextramethorphan of heroin addicted outpatients. Int J Clin Pharmacol Ther 1995; 33: 13-19.